Andrew D. Badley, MD, is Professor of Medicine in the Division of Infectious Diseases and HH Sheikh Khalifa Bin Zayed Al-Nahyan Professor of Infectious Diseases at the Mayo Clinic in Rochester, Minnesota. He received his medical degree from Dalhousie University in Halifax, Nova Scotia, Canada, before completing a residency in Internal Medicine and Clinician Investigator Training in Infectious Diseases at the Mayo Clinic. Dr. Badley is also Founder, President, and Chief Scientific Officer of Splissen Pharma, a company related to his published research, and he has been appointed Chair of the Mayo Clinic task force on SARS-CoV2/COVID-19 research, where he oversees all research activities, including clinical trials related to the virus and the disease.
At the Mayo Clinic, Dr. Badley oversees a successful basic and translational research laboratory program and treats patients with a variety of infectious diseases occurring as a consequence of being immunosuppressed due to HIV infection or prior receipt of a transplant. His research has led to more than 140 peer-reviewed publications, he has edited or co-edited three books, and he has written numerous book chapters. Dr. Badley has been appointed to many national and international scientific advisory committees, most notably the prestigious National Institutes of Health Recombinant DNA Advisory Committee.
Dr. Badley’s lab has had continuous federal funding for ~25 years, and his research has ranged from elucidating the most basic scientific concepts to conducting investigator-initiated clinical trials designed to complete the circle that links bench to bedside. He is a Fellow of the American College of Physicians, the Royal College of Physicians and Surgeons of Canada, and the Infectious Diseases Society of America; an elected member of The American Society for Clinical Investigation; and the recipient of numerous awards.
Dr. Badley’s research focus investigates the regulation of cell death and cell survival in infectious diseases, notably HIV, and how understanding these processes can lead to novel therapeutic strategies to reduce morbidity and mortality.